HUM vs RCUS · P/E 39, rev $117.76B vs rev $258.0M
Humana Inc (HUM) versus Arcus Biosciences Inc (RCUS) — a side-by-side from cached financials, not a winner call.
Humana Inc (HUM) is a healthcare plans company listed on NYSE.
Arcus Biosciences Inc (RCUS) is a biotechnology company listed on US.
Latest reported HUM revenue for 2024-12-31 was $117.76B. Net income was $1.21B. Revenue was up 10.7% from 2023-12-31 to 2024-12-31. HUM currently screens at market cap $43.46B and trailing P/E 38.6.
Latest reported RCUS revenue for 2024-12-31 was $258.0M. Net income was -$283.0M. Revenue was up 120.5% from 2023-12-31 to 2024-12-31. RCUS currently screens at market cap $885.2M.
HUM currently screens at market cap $43.46B and trailing P/E 38.6. RCUS currently screens at market cap $885.2M.
Not investment advice. Open the HUM and RCUS stock pages for the full models.
Not investment advice.